Anticoagulation Drugs

Managing antiplatelet therapy in thrombocytopenic patients with hematological malignancy
Anticoagulation Drugs

Managing antiplatelet therapy in thrombocytopenic patients with hematological malignancy

The use of antiplatelet therapy, prescribed for acute and chronic ischemic arterial disease, is frequently encountered in cancer patients. A clinical vignette-based experiment was designed to mimic the clinical scenarios in which decision-making occurs.

Read More
The safety of DOACs to treat VTE in patients with brain tumors
Anticoagulation Drugs

The safety of DOACs to treat VTE in patients with brain tumors

Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism, occurring in 20-30% depending on primary tumor type. Anticoagulant therapy for patients with brain tumors is challenging given concerns regarding risk of clinically significant intracranial hemorrhage, which occurs at a rate of between 2-20% in patients not receiving anticoagulation [3-4].

Read More
Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis
Anticoagulation Drugs

Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis

One of the most complex situations in the treatment of cancer-associated thrombosis is represented by oncological patients with thrombocytopenia...

Read More
Managing antithrombotic medication in thrombocytopenia
Anticoagulation Drugs

Managing antithrombotic medication in thrombocytopenia

Cancer is associated with an increased risk of venous but also arterial thrombosis1. Moreover, contemporary anticancer therapy and supportive care allow for treatment of older patients with comorbid diseases such as ischemic heart disease and atrial fibrillation...

Read More
New perspectives for the treatment of cancer-associated thrombosis
Anticoagulation Drugs

New perspectives for the treatment of cancer-associated thrombosis

Patients with cancer-associated thrombosis (CAT) exhibit a risk of venous thromboembolic (VTE) complications, which exceeds by far those expected in the general population, and prevail in patients with the most advanced stages of cancer

Read More
Management of bleeding complications in cancer patients on DOACs
Anticoagulation Drugs

Management of bleeding complications in cancer patients on DOACs

Major bleeding can be life or limb threatening and incurs substantial health care costs, whereas clinically relevant non-major bleeds are mainly very disturbing for the patients and may reduce their quality of life. Bleeding in patients with anticoagulation for venous thromboembolism (VTE) the incidence is front-loaded. Patients with a major bleeding are usually not given extended anticoagulant treatment.

Read More
Treatment of choice
Anticoagulation Drugs

Treatment of choice

Under construction. Please check back soon.

Read More